Dabrafenib (GSK2118436)

目录号:S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂,无细胞试验中IC50为0.7 nM,作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格 价格 库存 购买数量  
RMB 1481.39 现货
RMB 733.64 现货
RMB 1056.75 现货
RMB 1394.46 现货
RMB 2235.84 现货
RMB 3261.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

  • Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂,无细胞试验中IC50为0.7 nM,作用于B-Raf(wt)和c-Raf效果分别低7和9倍。
靶点
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
体外研究

Dabrafenib对Raf激酶具有选择性,对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-RafV600E激酶,导致ERK磷酸化降低和抑制细胞的增值,在特异性编码突变的B-RafV600E的癌细胞中细胞停滞在G1期。

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NEfrZ|dMcW6jc3WgRZN{[Xl? NY\qUHlTUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW|c3nu[{BETEN|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN MnjUNlQ6ODB4N{O=
SK-MEL-28 NIf4SWFMcW6jc3WgRZN{[Xl? NITpZ|cyKGh? M{XlTGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2= M3vHd|I1QTByNkez
HepG2 NV7LOlhNU2mwYYPlJGF{e2G7 NIPCU2VKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1? M1vHdVI1QTByNkez
COLO205 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DUVmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= M{LLUFI1QTByNkez
HepG2 MoG2SpVv[3Srb36gRZN{[Xl? NV\ONFNwPDVibXnu NEnlUZFFVVOR NE[4cpVKdmirYnn0bY9vKG:oIFHsb|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m|IIfpeIghUUN3MDDv[kA{NjdizszN MYmyOFkxODZ5Mx?=
HFF NHjpTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDZbFIyOCEQvF2= MWG3NkBp M4[5S2ROW09? MYrJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN MonzNlM5PDRyM{i=
SK-MEL-28 NXvSd|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHOVVcyOCEQvF2= MYW3NkBp NY\lWGEzTE2VTx?= M3LHTmlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0> MkjDNlM5PDRyM{i=
A375P-F11 NF\wSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? NF35[3A4OiCq MnGxSG1UVw>? NHL5RnpKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO NFL2WJkzOzh2NECzPC=>
MALME-3M MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K5cFExKM7:TR?= MXS3NkBp NGG2XYtFVVOR MULJR|UxRTFibl2= MV6yN|g1PDB|OB?=
UACC-62 M3jDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? M2S3eFczKGh? M2f6dmROW09? MX;JR|UxRTFibl2= NH3RRVMzOzh2NECzPC=>
C32TG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS0foVzOTBizszN MlX6O|IhcA>? NH3VWWlFVVOR NV73NWJ5UUN3ME2xJI5O MoXTNlM5PDRyM{i=
SK-MEL-1 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC1NVAh|ryP MV63NkBp MX7EUXNQ M1PXV2lEPTB;MjDuUS=> MWSyN|g1PDB|OB?=
M14 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC2e|VbOTBizszN NF;lcHk4OiCq NXTpUYVkTE2VTx?= NGPyco9KSzVyPUKgcm0> NVWwSYt[OjN6NESwN|g>
SK-MEL-28 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPoNVAh|ryP MofrO|IhcA>? MXzEUXNQ MmnaTWM2OD1|IH7N NEnMb2ozOzh2NECzPC=>
A375 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\rN4NFOTBizszN NXjqSJlIPzJiaB?= M3TPRWROW09? M4j3S2lEPTB;NDDuUS=> M3v3R|I{QDR2MEO4
DU-4475 NVTZfoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNEDPxE1? MV:3NkBp NX3ZZ|V6TE2VTx?= NInmfIRKSzVyPUWgcm0> MVGyN|g1PDB|OB?=
UACC-257 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPoNnAyOCEQvF2= M12yWlczKGh? M4fNdGROW09? M3X6bmlEPTB;NjDuUS=> M{L2OlI{QDR2MEO4
Colo 205 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGw[4YyOCEQvF2= NXzwbGFwPzJiaB?= MVHEUXNQ MlrlTWM2OD15IH7N M1Xxd|I{QDR2MEO4
SK-MEL-3 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQNVAh|ryP NVHBb4ZMPzJiaB?= MmDCSG1UVw>? NUC2blJ3UUN3ME23JI5O NU\WepBpOjN6NESwN|g>
SH-4 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O2PFExKM7:TR?= NWHuOWZvPzJiaB?= MXPEUXNQ NFTp[ZZKSzVyPUigcm0> NHL6O40zOzh2NECzPC=>
A101D NWTLbWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? MYm3NkBp NUDN[5dpTE2VTx?= NYfUNIozUUN3ME25JI5O MmnaNlM5PDRyM{i=
ES-2 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTGZWdqOTBizszN M3noeVczKGh? NY\HUW5bTE2VTx?= MofRTWM2OD13MzDuUS=> MkHONlM5PDRyM{i=
HT-29 NFjBVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLkW2JvOTBizszN MUW3NkBp M{PhbmROW09? MYHJR|UxRTZ4IH7N NYfqbIpmOjN6NESwN|g>
SW1417 NVKyU2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj6cHl2OTBizszN NVPHb2NSPzJiaB?= M161c2ROW09? MVHJR|UxRTF3ODDuUS=> NHLxdpMzOzh2NECzPC=>
SW872 NI\oT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? NIDpc2E4OiCq NHHufllFVVOR NW\hT5A4UUN3ME2zO|chdk1? M{HwOlI{QDR2MEO4
RKO NXvTbYxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nu[FExKM7:TR?= M3zrbVczKGh? NHTnS4VFVVOR MWHJR|UxRTJwNUKyJO69VQ>? NYX6T3p3OjN6NESwN|g>
A673 M1Tiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHoS45zOTBizszN MVe3NkBp MYnEUXNQ M4ezNWlEPTB;MUCg{txO MX[yN|g1PDB|OB?=
GCT MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof0NVAh|ryP M3Px[lczKGh? MUfEUXNQ NWPQO21JUUN3ME2xNEDPxE1? NITYc2wzOzh2NECzPC=>
WM-115 NEm4WJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPSVExKM7:TR?= NWnwN4FZPzJiaB?= M3POS2ROW09? NGnvSYtKSzVyPUWgcm0> Ml;GNlM5PDRyM{i=
YUMAC MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDTVExKM7:TR?= NX;xNGRUPzJiaB?= MlTCSG1UVw>? NI\We3BKSzVyPUWgcm0> MonzNlM5PDRyM{i=
OV-90 M4jPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? MX[3NkBp M{XpeGROW09? M1LyOGlEPTB;Mkmgcm0> NFmyZnAzOzh2NECzPC=>
NCI-H508 NIPheFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXNO5QyOCEQvF2= NEXIWWI4OiCq MorlSG1UVw>? Mn;VTWM2OD1zMDFOwG0> NYPaU|F6OjN6NESwN|g>
MDA-MB-231 NF[1fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3T4YyOCEQvF2= NID2XZA4OiCq MXzEUXNQ MYTJR|UxRTFyIN88US=> NX;MVnBXOjN6NESwN|g>
SW756 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC5THIyOCEQvF2= NVvsfZBVPzJiaB?= MnTTSG1UVw>? MlPJTWM2OD1zMDFOwG0> NIDuWlEzOzh2NECzPC=>
SW-837 NFHmOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG1VVQyOCEQvF2= Mln1O|IhcA>? NHnT[G9FVVOR NWTa[pk6UUN3ME2xNEDPxE1? M1\mVVI{QDR2MEO4
UMUC-3 NVzPNo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? MmrJO|IhcA>? MoPNSG1UVw>? MXfJR|UxRTFyIN88US=> NIHjPJEzOzh2NECzPC=>
LS-174T M{TWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fMSFExKM7:TR?= MY[3NkBp M3XBPGROW09? NGjxOI5KSzVyPUGwJO69VQ>? NVfYNmhGOjN6NESwN|g>
A549 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnjWZgyOCEQvF2= NW[1OmNOPzJiaB?= NVHrd457TE2VTx?= M1T3W2lEPTB;MUCg{txO M{nDb|I{QDR2MEO4
SHP-77 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjGWIhqOTBizszN MXW3NkBp NGDlS5NFVVOR MoDGTWM2OD1zMDFOwG0> NE\aVWwzOzh2NECzPC=>
SW480 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXwZmxIOTBizszN M2r0SVczKGh? MVrEUXNQ M2C0NWlEPTB;MUCg{txO M{HpUlI{QDR2MEO4
DLD-1 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jnXFExKM7:TR?= MnfCO|IhcA>? MXvEUXNQ NH:x[lhKSzVyPUGwJO69VQ>? MlP0NlM5PDRyM{i=
HCT-116 NW\6VZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknxNVAh|ryP M{TRVFczKGh? MofWSG1UVw>? NYjueFZtUUN3ME2xNEDPxE1? Ml;3NlM5PDRyM{i=
NCI-H747 M3HZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1c|BMOTBizszN MYe3NkBp NH\SenFFVVOR MYnJR|UxRTFyIN88US=> NX\vZVg5OjN6NESwN|g>
T-84 M1vMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBWYJoOTBizszN NHiydJY4OiCq MWLEUXNQ MljGTWM2OD1zMDFOwG0> MViyN|g1PDB|OB?=
NCI-H460 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ZXmRiOTBizszN MkTlO|IhcA>? M1KxUWROW09? MYjJR|UxRTFyIN88US=> M{\G[lI{QDR2MEO4
Calu-6 M4W4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnhNVAh|ryP NGn0WYQ4OiCq MYXEUXNQ NHjTS3pKSzVyPUGwJO69VQ>? NVqx[oE3OjN6NESwN|g>
HCC-2998 NUPUdoFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1frc|ExKM7:TR?= NEX4d2Q4OiCq NGLJXZRFVVOR NV\TXoFvUUN3ME2xNEDPxE1? M4flWFI{QDR2MEO4
LS1034 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\BVXUyOCEQvF2= NHP6Vo84OiCq MULEUXNQ NYnGellMUUN3ME2xNEDPxE1? MlK4NlM5PDRyM{i=
CHP-212 M1PTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvwV2k6OTBizszN MU[3NkBp NUDxNoZCTE2VTx?= MnmyTWM2OD1zMDFOwG0> NXvnVVJlOjN6NESwN|g>
SK-N-AS NWK1cVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHD[IFVOTBizszN MlriO|IhcA>? Mn34SG1UVw>? M2\SOGlEPTB;MUCg{txO MlzSNlM5PDRyM{i=
BFTC-905 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNEDPxE1? MlzsO|IhcA>? MUnEUXNQ NHexNWlKSzVyPUGwJO69VQ>? NWDJc|F4OjN6NESwN|g>
HuT78 NX7QVGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGzOHV7OTBizszN NGfnd4E4OiCq MkLzSG1UVw>? NVrnZ5RIUUN3ME21NkBvVQ>? MUWyN|g1PDB|OB?=
RPMI-8226 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;p[GhvOTBizszN M2C5W|czKGh? M360VGROW09? M1HBdWlEPTB;Mk[zJI5O M1nNVlI{QDR2MEO4
BC-3 M{DjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjhUIIyOCEQvF2= NXiwO3V7PzJiaB?= M3zMWmROW09? NILETG5KSzVyPUK3O{BvVQ>? M121XlI{QDR2MEO4
ACHN M4CxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNEDPxE1? NHPVd5A4OiCq M4PORmROW09? MXzJR|UxRTJ7NDDuUS=> M4i2RVI{QDR2MEO4
JRT3-T35 NVi1dGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTjbodkOTBizszN M1XzeVczKGh? M2TCV2ROW09? MYPJR|UxRTJ7NTDuUS=> NYLvXVJSOjN6NESwN|g>
SK-MES-1 NGHlfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXUcZJXOTBizszN NFLQcVc4OiCq NFnmT5FFVVOR MnfWTWM2OD1|Mkmgcm0> NXy3Z49zOjN6NESwN|g>
CESS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O0XFExKM7:TR?= M2K3N|czKGh? NIf0R2RFVVOR NX3wNY9qUUN3ME20PVchdk1? MoLnNlM5PDRyM{i=
H4 NHn3dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? NUDrdGdCPzJiaB?= M1LQS2ROW09? MnexTWM2OD14MUmgcm0> MWKyN|g1PDB|OB?=
BC-1 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnlR4Y1OTBizszN MlHDO|IhcA>? M3K0O2ROW09? MVTJR|UxRTdyNDDuUS=> M3XEcFI{QDR2MEO4
DB NFLtfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxNEDPxE1? MkfzO|IhcA>? MWrEUXNQ NFHnWFJKSzVyPUi3N{BvVQ>? Ml;WNlM5PDRyM{i=
RPMI-6666 NHyybWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XBcVExKM7:TR?= MWq3NkBp MXfEUXNQ NYmzUpM{UUN3ME25Nlghdk1? NEf3NnMzOzh2NECzPC=>
MC/CAR MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;kfFExKM7:TR?= MUS3NkBp MVXEUXNQ M2\hfmlEPTB;MT6wNFIh|ryP NXHxR5NXOjN6NESwN|g>
SNU-1 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG4NVAh|ryP M1XaWlczKGh? NX;CeHdTTE2VTx?= NEfHTppKSzVyPUGuOVAyKM7:TR?= Mlu0NlM5PDRyM{i=
CEM/C1 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmxNEDPxE1? MmLrO|IhcA>? M3\VUmROW09? MW\JR|UxRTFwN{ezJO69VQ>? NXviVJVIOjN6NESwN|g>
GDM-1 NHPLcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq1WGcyOCEQvF2= MX:3NkBp Mo\xSG1UVw>? M37FS2lEPTB;MT65PVch|ryP NGftd3QzOzh2NECzPC=>
HT-1080 M2LTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xNEDPxE1? NFnNeVI4OiCq MVvEUXNQ MofhTWM2OD1{LkCwOEDPxE1? MVOyN|g1PDB|OB?=
HL-60 M3fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLmNVAh|ryP NGLXTnA4OiCq M{fzZmROW09? M{T0[WlEPTB;Mj6xO|gh|ryP M1jCR|I{QDR2MEO4
C3A MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? MWi3NkBp MVrEUXNQ M2\yPGlEPTB;NT60NVQh|ryP MkfsNlM5PDRyM{i=
MES-SA NEfnWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNEDPxE1? M121dlczKGh? NHO4eWVFVVOR M2PvSGlEPTB;Nj65PFkh|ryP NUXMbpZHOjN6NESwN|g>
22Rv1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTnU21pOTBizszN MkLqO|IhcA>? MkjISG1UVw>? NUXQZYtpUUN3ME2xNEDPxE1? M3z2XlI{QDR2MEO4
647-V MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknBNVAh|ryP NXLNTJZ7PzJiaB?= MXHEUXNQ M{HVN2lEPTB;MUCg{txO M1i2OlI{QDR2MEO4
786-O M1HCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHpV|M5OTBizszN MXW3NkBp M{XtemROW09? NFf6OZhKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
A172 NVjUcnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4cVExKM7:TR?= MVK3NkBp NEHCVHJFVVOR MXPJR|UxRTFyIN88US=> MlLMNlM5PDRyM{i=
A204 NID1c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v0[FExKM7:TR?= M324[lczKGh? MWPEUXNQ MkjlTWM2OD1zMDFOwG0> MV[yN|g1PDB|OB?=
A427 NWDPdZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KyPFExKM7:TR?= MVW3NkBp NVHhd41xTE2VTx?= MYDJR|UxRTFyIN88US=> NYm5VpNLOjN6NESwN|g>
A431 NFnXcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxNEDPxE1? MYO3NkBp MXTEUXNQ NYHHT2hKUUN3ME2xNEDPxE1? MoqxNlM5PDRyM{i=
A2780 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\5NVAh|ryP NUnnVG1mPzJiaB?= M1e1U2ROW09? MYXJR|UxRTFyIN88US=> M1vBRlI{QDR2MEO4
ARH-77 M3z6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJ[VExKM7:TR?= NHm3cJk4OiCq M3fYPGROW09? MUfJR|UxRTFyIN88US=> MX:yN|g1PDB|OB?=
Be(2)C NVTwVGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xNEDPxE1? MWq3NkBp M3LMS2ROW09? NGHYdlRKSzVyPUGwJO69VQ>? NXT4RphZOjN6NESwN|g>
BT-20 M3vr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? Mnr5O|IhcA>? NUXwZ3FyTE2VTx?= MnXtTWM2OD1zMDFOwG0> NH;SdVczOzh2NECzPC=>
BxPc3 M4HtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVN|cyOCEQvF2= MWW3NkBp MoH2SG1UVw>? NFLvb3RKSzVyPUGwJO69VQ>? NHzxVFEzOzh2NECzPC=>
C-4 I MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37EeVExKM7:TR?= MYC3NkBp NGLk[GJFVVOR MmrPTWM2OD1zMDFOwG0> MmnlNlM5PDRyM{i=
C33A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISzNXgyOCEQvF2= NX;Ido9GPzJiaB?= NGXWXXJFVVOR NU[1d2ZuUUN3ME2xNEDPxE1? NFK3UHYzOzh2NECzPC=>
CAL-27 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3uNVAh|ryP MkW3O|IhcA>? NVjPRWtvTE2VTx?= M2\lXmlEPTB;MUCg{txO MYWyN|g1PDB|OB?=
CAL-62 NF[3UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxNEDPxE1? NFP1cXY4OiCq MWrEUXNQ MmXTTWM2OD1zMDFOwG0> M3G5VFI{QDR2MEO4
Calu-3 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6NVAh|ryP MWm3NkBp NEfMOFJFVVOR NELlUIJKSzVyPUGwJO69VQ>? M3zxVlI{QDR2MEO4
CaOV3 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnZbVd5OTBizszN MX[3NkBp MVrEUXNQ NFXEV2FKSzVyPUGwJO69VQ>? MXWyN|g1PDB|OB?=
CGTHW1 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1TFUyOCEQvF2= MlXVO|IhcA>? M3S3XWROW09? NYDITJpUUUN3ME2xNEDPxE1? NWDDepROOjN6NESwN|g>
CHL-1 NHOyT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfSW4YyOCEQvF2= M334PVczKGh? MX\EUXNQ MoK0TWM2OD1zMDFOwG0> NG\ZU|MzOzh2NECzPC=>
Colo320DM MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPmOmV[OTBizszN M1zneVczKGh? MUDEUXNQ NUC5cphpUUN3ME2xNEDPxE1? MVSyN|g1PDB|OB?=
Colo704 NGDkb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XB[VExKM7:TR?= MlK4O|IhcA>? MVLEUXNQ NYjvNYFwUUN3ME2xNEDPxE1? MlLLNlM5PDRyM{i=
COR-L23 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jI[FExKM7:TR?= M1;Rc|czKGh? NH\NTWJFVVOR MY\JR|UxRTFyIN88US=> MYqyN|g1PDB|OB?=
CRO-AP2 M2nDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxNEDPxE1? NHfwUFI4OiCq MU\EUXNQ MoPYTWM2OD1zMDFOwG0> MUeyN|g1PDB|OB?=
Daudi MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxNEDPxE1? NWrNNmNrPzJiaB?= NHnFOYNFVVOR MnfYTWM2OD1zMDFOwG0> NE\LN5YzOzh2NECzPC=>
DOTC 24510 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInid5YyOCEQvF2= NEjy[Wk4OiCq MV7EUXNQ MXTJR|UxRTFyIN88US=> NHi2TIEzOzh2NECzPC=>
DU-145 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGxNEDPxE1? MojwO|IhcA>? NGn1XlVFVVOR MV;JR|UxRTFyIN88US=> NU[ze5E4OjN6NESwN|g>
EB-3 M{jjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iNVAh|ryP MX[3NkBp NUTrSGdFTE2VTx?= M1nDNWlEPTB;MUCg{txO NIKxO4IzOzh2NECzPC=>
EFM-19 NX24XZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1THbFExKM7:TR?= NW\NeoQ5PzJiaB?= NHvCUZNFVVOR MmHQTWM2OD1zMDFOwG0> M4HOTlI{QDR2MEO4
EKVX MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvvNVAh|ryP MX[3NkBp MorPSG1UVw>? M{HPOWlEPTB;MUCg{txO NIfyfoMzOzh2NECzPC=>
FaDu M4jiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHEcldNOTBizszN Mmr2O|IhcA>? NWj6Tow4TE2VTx?= NHnIXpJKSzVyPUGwJO69VQ>? NGDEN28zOzh2NECzPC=>
G401 NYHYNGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2eWZwOTBizszN MVO3NkBp M1n0UWROW09? MkP4TWM2OD1zMDFOwG0> MV6yN|g1PDB|OB?=
HCC-70 NXH0PHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? NHPLNFQ4OiCq M4rqbWROW09? NGrFWZFKSzVyPUGwJO69VQ>? NHrp[WEzOzh2NECzPC=>
HCC-1954 NGTifZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTFeXAyOCEQvF2= MkPGO|IhcA>? NH\nbHdFVVOR NGPYVnNKSzVyPUGwJO69VQ>? MXOyN|g1PDB|OB?=
Hela NHrTR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hyc|ExKM7:TR?= M2HURlczKGh? MXjEUXNQ NU\rcYJJUUN3ME2xNEDPxE1? NULwUGliOjN6NESwN|g>
Hep3B NWHiNVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIS49kOTBizszN NHThO284OiCq M{jE[2ROW09? MoD3TWM2OD1zMDFOwG0> Ml75NlM5PDRyM{i=
HMCB NIHUNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXb4ZtOTBizszN NVTLWYxVPzJiaB?= NVLUOmFGTE2VTx?= Mln6TWM2OD1zMDFOwG0> M2H3WVI{QDR2MEO4
HN5 M{XvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPET2oyOCEQvF2= Mo\QO|IhcA>? NUDOcm9rTE2VTx?= M4XxUmlEPTB;MUCg{txO Mkj3NlM5PDRyM{i=
HOS M2rNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNEDPxE1? MWS3NkBp M4X6[mROW09? NYLT[IlqUUN3ME2xNEDPxE1? NInoeG4zOzh2NECzPC=>
HPAF-II MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyNVAh|ryP NYLHS5Y4PzJiaB?= MXfEUXNQ MYTJR|UxRTFyIN88US=> M4LKdlI{QDR2MEO4
Hs746.T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[4NVAh|ryP NELXeY84OiCq M3znZmROW09? NXj2NosxUUN3ME2xNEDPxE1? NHi0W3gzOzh2NECzPC=>
HT NXvFbGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNEDPxE1? M3fkbFczKGh? Mni4SG1UVw>? NIrmTVVKSzVyPUGwJO69VQ>? NVuwO5E2OjN6NESwN|g>
HT-3 M1P1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNEDPxE1? MX[3NkBp NIHFWY1FVVOR MnTsTWM2OD1zMDFOwG0> NGn5cFUzOzh2NECzPC=>
HuNS-1 NEHqT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPYPHAyOCEQvF2= M1jvU|czKGh? MUXEUXNQ MVXJR|UxRTFyIN88US=> MlvtNlM5PDRyM{i=
IGROV1 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfSO3kyOCEQvF2= M4WxWFczKGh? M4j0e2ROW09? NGrSdGpKSzVyPUGwJO69VQ>? MlzVNlM5PDRyM{i=
J82 M3TNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInUUVIyOCEQvF2= M1jp[lczKGh? Mn7jSG1UVw>? MULJR|UxRTFyIN88US=> MojKNlM5PDRyM{i=
JM1 NIftT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0N|ExKM7:TR?= MlTSO|IhcA>? MUfEUXNQ NGfEdpBKSzVyPUGwJO69VQ>? NFvRZlQzOzh2NECzPC=>
Kato III Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? MWm3NkBp MWjEUXNQ M3XPdmlEPTB;MUCg{txO M1TYW|I{QDR2MEO4
KHOS-240S NUTFS4g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxNEDPxE1? MVu3NkBp M1[5SmROW09? NHHWVHRKSzVyPUGwJO69VQ>? MWeyN|g1PDB|OB?=
KM-12 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYToZmJvOTBizszN M1HjSVczKGh? MUDEUXNQ Mm\6TWM2OD1zMDFOwG0> MYWyN|g1PDB|OB?=
KPL-1 NWS0bIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PnbFExKM7:TR?= MkLHO|IhcA>? MlPMSG1UVw>? MnHCTWM2OD1zMDFOwG0> M2j4flI{QDR2MEO4
KYSE-30 NEC4VJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[2Tm5LOTBizszN M1jOeFczKGh? NX;2TFhpTE2VTx?= MVnJR|UxRTFyIN88US=> MVeyN|g1PDB|OB?=
LNCaP MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDPRWgyOCEQvF2= MUm3NkBp NEXzTFVFVVOR NWTiXVBPUUN3ME2xNEDPxE1? M1ntU|I{QDR2MEO4
MCF-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjUPFQ{OTBizszN NV;jeXExPzJiaB?= MWrEUXNQ NUG3OI1VUUN3ME2xNEDPxE1? MWWyN|g1PDB|OB?=
MC-IXC M2TiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNEDPxE1? M13jOFczKGh? NW\RTooxTE2VTx?= MYrJR|UxRTFyIN88US=> NW\TcHlROjN6NESwN|g>
MDA-MB-175 VII M{\kTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\qdYhLOTBizszN M{K0[VczKGh? MWfEUXNQ NXPjN29sUUN3ME2xNEDPxE1? M1XOW|I{QDR2MEO4
MDA-MB-468 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLPUmwyOCEQvF2= MmnWO|IhcA>? MUPEUXNQ M{HRR2lEPTB;MUCg{txO MYWyN|g1PDB|OB?=
MiaPaCa NIH2[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\NXIgyOCEQvF2= M3T4V|czKGh? MkTOSG1UVw>? NH3UfVhKSzVyPUGwJO69VQ>? NWqxcI1EOjN6NESwN|g>
Molt-4 NIS4SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvFNVAh|ryP MWS3NkBp M3[yW2ROW09? NXu1dZFxUUN3ME2xNEDPxE1? NHvzVHQzOzh2NECzPC=>
NCI-ADR/RES M1yyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6SIMyOCEQvF2= M3TpXVczKGh? NIHPV5RFVVOR NIDSO2tKSzVyPUGwJO69VQ>? MYeyN|g1PDB|OB?=
NCI-H69 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\XelExKM7:TR?= NGr3fnI4OiCq MYnEUXNQ MYnJR|UxRTFyIN88US=> NWTOPHljOjN6NESwN|g>
NCI-H82 NYPmc5cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? NGHlUnc4OiCq M1zFZ2ROW09? MlmzTWM2OD1zMDFOwG0> M13mWVI{QDR2MEO4
NCI-N87 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID5Z2gyOCEQvF2= MofsO|IhcA>? M1zFbGROW09? NHLacYJKSzVyPUGwJO69VQ>? NGDLemkzOzh2NECzPC=>
NCI-H146 NEHWW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyfFExKM7:TR?= NYLGe5UyPzJiaB?= NXK5Uno2TE2VTx?= MV;JR|UxRTFyIN88US=> NUHw[Hd[OjN6NESwN|g>
NCI-H157 NXm4U3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQXmNkOTBizszN MUe3NkBp NYLLNHh4TE2VTx?= NXm2[IxpUUN3ME2xNEDPxE1? NGnBSGszOzh2NECzPC=>
NCI-H187 NWqxS4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? NIrtV5g4OiCq M2exdWROW09? NUfyZ4I6UUN3ME2xNEDPxE1? M{\nZlI{QDR2MEO4
NCI-H209 NUjnR3RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNEDPxE1? M{[wNlczKGh? NGTpO3lFVVOR MoL6TWM2OD1zMDFOwG0> MV6yN|g1PDB|OB?=
NCI-H226 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e2RVExKM7:TR?= NHjEPZM4OiCq NIPxV|BFVVOR MXHJR|UxRTFyIN88US=> MV:yN|g1PDB|OB?=
NCI-H292 M{jadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\lfocyOCEQvF2= NXjEWWNnPzJiaB?= M3zoWWROW09? NFTjSlhKSzVyPUGwJO69VQ>? NUDrSGE4OjN6NESwN|g>
NCI-H322 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUexNEDPxE1? NXfSVnJVPzJiaB?= MlS1SG1UVw>? MlrzTWM2OD1zMDFOwG0> MV[yN|g1PDB|OB?=
NCI-H358 NHjxNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3yUlk5OTBizszN NG\JPVM4OiCq MnvXSG1UVw>? NYr0UZZGUUN3ME2xNEDPxE1? NXjOb4U1OjN6NESwN|g>
NCI-H520 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\YOJgyOCEQvF2= MX23NkBp MV7EUXNQ NXfJNJJNUUN3ME2xNEDPxE1? NGPzeW8zOzh2NECzPC=>
NCI-H526 NVHqV|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOxNVAh|ryP M2LOS|czKGh? NX7LZVZuTE2VTx?= MlX3TWM2OD1zMDFOwG0> MlfqNlM5PDRyM{i=
NCI-H630 M4nYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DST|ExKM7:TR?= MX:3NkBp NUG0fGFvTE2VTx?= MoLWTWM2OD1zMDFOwG0> NXH3XnpWOjN6NESwN|g>
NCI-H661 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? M3e4ZlczKGh? MorESG1UVw>? NV7IV2Y2UUN3ME2xNEDPxE1? MXeyN|g1PDB|OB?=
NCI-H716 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPKNW4yOCEQvF2= MXu3NkBp NVKxWXhNTE2VTx?= M4\1VGlEPTB;MUCg{txO M4Pv[FI{QDR2MEO4
NCI-H1563 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj3NIFCOTBizszN MV23NkBp MnHaSG1UVw>? M1rCUGlEPTB;MUCg{txO NInSbXozOzh2NECzPC=>
NCI-H1792 NIPITXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjNVAh|ryP NI\iT4c4OiCq MlLHSG1UVw>? MnHVTWM2OD1zMDFOwG0> NH7tNXQzOzh2NECzPC=>
NCI-H2030 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXKNVAh|ryP NHrUO3E4OiCq MmD4SG1UVw>? NVLMe5BoUUN3ME2xNEDPxE1? M3\nW|I{QDR2MEO4
NCI-H2052 NInGNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn2RW9nOTBizszN M{jXSVczKGh? M37NXWROW09? NFfDeoJKSzVyPUGwJO69VQ>? Ml3WNlM5PDRyM{i=
NCI-H2122 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;NfoMyOCEQvF2= NU\QdJZVPzJiaB?= NGLpcZpFVVOR NUjMeoVNUUN3ME2xNEDPxE1? MmLBNlM5PDRyM{i=
NCI-H2228 M16ye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7yV2VJOTBizszN NXLtV49SPzJiaB?= NUDleJpCTE2VTx?= NWj1e2VuUUN3ME2xNEDPxE1? MYSyN|g1PDB|OB?=
OE-19 NX3We4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml70NVAh|ryP NITWTVA4OiCq NITPT|VFVVOR NWXIZ4p7UUN3ME2xNEDPxE1? M1P0OFI{QDR2MEO4
OE-21 NHWxR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PLdFExKM7:TR?= MWW3NkBp M3TPVWROW09? MVvJR|UxRTFyIN88US=> M{i4XFI{QDR2MEO4
OE-33 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNEDPxE1? MVi3NkBp NVXuU4dmTE2VTx?= NWrV[ZQzUUN3ME2xNEDPxE1? M3ryeVI{QDR2MEO4
OVCAR-3 NIPVVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrhNFcyOCEQvF2= MmHtO|IhcA>? M17xOWROW09? NInzUIZKSzVyPUGwJO69VQ>? Ml7VNlM5PDRyM{i=
OVCAR-4 M3HNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP0[noyOCEQvF2= MYS3NkBp MUnEUXNQ NFvWSFZKSzVyPUGwJO69VQ>? NEfFXJgzOzh2NECzPC=>
OVCAR-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxNEDPxE1? MmjEO|IhcA>? NGHsfYZFVVOR NYfOPYp{UUN3ME2xNEDPxE1? MWGyN|g1PDB|OB?=
P3HR-1 M{flbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X5W|ExKM7:TR?= NWHwUmp6PzJiaB?= MXrEUXNQ MoTSTWM2OD1zMDFOwG0> MkW4NlM5PDRyM{i=
PC-3 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6U4MyOCEQvF2= NXjTNYdnPzJiaB?= MoruSG1UVw>? M33GSGlEPTB;MUCg{txO MU[yN|g1PDB|OB?=
Raji NVG3cYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\X[pAyOCEQvF2= MUG3NkBp NUG0fJNZTE2VTx?= MknMTWM2OD1zMDFOwG0> NYD6NpZzOjN6NESwN|g>
RD NETPPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorzNVAh|ryP MWW3NkBp M1T5emROW09? NHLxRo9KSzVyPUGwJO69VQ>? NIe4fXUzOzh2NECzPC=>
RD-ES M{jtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD0RXJHOTBizszN Mmj2O|IhcA>? NFXGfo1FVVOR MWnJR|UxRTFyIN88US=> M2jLfFI{QDR2MEO4
RL MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInBR|EyOCEQvF2= MWq3NkBp MVrEUXNQ MYnJR|UxRTFyIN88US=> M13zc|I{QDR2MEO4
SaOS2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP1NVAh|ryP MkntO|IhcA>? NXXL[G8{TE2VTx?= MlqzTWM2OD1zMDFOwG0> MUCyN|g1PDB|OB?=
SCC-9 M4P3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWzO3dkOTBizszN M2WyPVczKGh? M{H4b2ROW09? M4ex[mlEPTB;MUCg{txO NIHJT5czOzh2NECzPC=>
SCC-12 M2Kye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0TVExKM7:TR?= MWq3NkBp MV7EUXNQ NYfRbZhFUUN3ME2xNEDPxE1? MUmyN|g1PDB|OB?=
SCC-13 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTXbo9HOTBizszN NGXWfGM4OiCq M{jNRmROW09? MWjJR|UxRTFyIN88US=> MXGyN|g1PDB|OB?=
SCC-15 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PPcFExKM7:TR?= M3u5SVczKGh? NETPcpRFVVOR MmnjTWM2OD1zMDFOwG0> NV7ObW9EOjN6NESwN|g>
SCC-25 M1jmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrOXGEyOCEQvF2= MnnwO|IhcA>? M4P2UmROW09? NH;mOnZKSzVyPUGwJO69VQ>? NGW2XYczOzh2NECzPC=>
SCLC-3 NWjDTJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jzS|ExKM7:TR?= NWfhN|ZUPzJiaB?= M2C5UWROW09? MnywTWM2OD1zMDFOwG0> MUeyN|g1PDB|OB?=
SF-268 NHT5NnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNEDPxE1? NVLyeos6PzJiaB?= NWDjeFhmTE2VTx?= M4rldGlEPTB;MUCg{txO M1XQXVI{QDR2MEO4
SF-295 NIfQcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLGbHptOTBizszN NHrLfZk4OiCq NELSZ4NFVVOR NYHC[FNDUUN3ME2xNEDPxE1? MUCyN|g1PDB|OB?=
SJRH30 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PTWVExKM7:TR?= M4q0bFczKGh? MYnEUXNQ MVTJR|UxRTFyIN88US=> NYjBcJluOjN6NESwN|g>
SK-BR-3 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaUlExKM7:TR?= MoPlO|IhcA>? NX\KPZoyTE2VTx?= MnmwTWM2OD1zMDFOwG0> MXWyN|g1PDB|OB?=
SK-LMS-1 NIq3cJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxNEDPxE1? MlPRO|IhcA>? NGrHN3pFVVOR NVf2b5JEUUN3ME2xNEDPxE1? MWKyN|g1PDB|OB?=
SK-N-DZ NWTXT3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5TVExKM7:TR?= MmfiO|IhcA>? NFfFSGZFVVOR M4DUU2lEPTB;MUCg{txO MkLWNlM5PDRyM{i=
SK-N-F1 M1Hlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln2NVAh|ryP MWe3NkBp NIHyfIxFVVOR MoDOTWM2OD1zMDFOwG0> MWGyN|g1PDB|OB?=
SKOV-3 NV;iZ4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixNEDPxE1? MXi3NkBp Ml3TSG1UVw>? MULJR|UxRTFyIN88US=> NYLoN3VoOjN6NESwN|g>
SK-UT-1 NIm2OZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17JUlExKM7:TR?= M{H5blczKGh? MlzLSG1UVw>? NVzDR5dOUUN3ME2xNEDPxE1? NHLkblIzOzh2NECzPC=>
SN12C M4fTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzWFExKM7:TR?= MnfBO|IhcA>? MnHySG1UVw>? M2XqN2lEPTB;MUCg{txO M{DwflI{QDR2MEO4
SNB-19 M4jP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV34UZNDOTBizszN M4XvS|czKGh? NWL1fld1TE2VTx?= MmPNTWM2OD1zMDFOwG0> NWDsT|FFOjN6NESwN|g>
SNU-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jSO|ExKM7:TR?= MXS3NkBp M1zJdmROW09? M4DPWWlEPTB;MUCg{txO MlvGNlM5PDRyM{i=
SNU-16 M37Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxNEDPxE1? NVnmeVY4PzJiaB?= M1LVdWROW09? MYrJR|UxRTFyIN88US=> MXyyN|g1PDB|OB?=
SNU-398 M2G4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zxNlExKM7:TR?= NIHaZ2M4OiCq MWXEUXNQ NHPHOGJKSzVyPUGwJO69VQ>? Mlu3NlM5PDRyM{i=
SNU-449 M1L6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsNY0yOCEQvF2= M3;4e|czKGh? MnzGSG1UVw>? M4j3XWlEPTB;MUCg{txO MYSyN|g1PDB|OB?=
SR MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTPXFM2OTBizszN NXmzeJFQPzJiaB?= NITI[llFVVOR NYPiWpBmUUN3ME2xNEDPxE1? M3vEbFI{QDR2MEO4
ST486 NG\IdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNEDPxE1? MUi3NkBp MlzGSG1UVw>? NUfPfmY4UUN3ME2xNEDPxE1? NFHSS2gzOzh2NECzPC=>
SW579 NFHyO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNEDPxE1? NGHKfFQ4OiCq MUTEUXNQ NY\3VphnUUN3ME2xNEDPxE1? NH;aV4kzOzh2NECzPC=>
SW684 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M131eFExKM7:TR?= NGH4UZI4OiCq Ml7oSG1UVw>? NVXrbphbUUN3ME2xNEDPxE1? NXLSRoQzOjN6NESwN|g>
SW-780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO0TXMyOCEQvF2= MV63NkBp M2D4WmROW09? Mn;DTWM2OD1zMDFOwG0> M4nOc|I{QDR2MEO4
SW900 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNEDPxE1? NIHFZZU4OiCq NHXEV4tFVVOR MWTJR|UxRTFyIN88US=> MYGyN|g1PDB|OB?=
SW1088 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLDUWsyOCEQvF2= MYS3NkBp M3z3Z2ROW09? MWfJR|UxRTFyIN88US=> MXWyN|g1PDB|OB?=
SW1463 NXLO[YsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XqNlExKM7:TR?= M3XYW|czKGh? MWjEUXNQ M2S5XGlEPTB;MUCg{txO NXS5d49qOjN6NESwN|g>
SW1990 M3;6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSRYc2OTBizszN NUC3VZFZPzJiaB?= MknPSG1UVw>? NFPKRXVKSzVyPUGwJO69VQ>? MVKyN|g1PDB|OB?=
T47D NV3hbXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1NVAh|ryP MUG3NkBp MUXEUXNQ NWPBVJJtUUN3ME2xNEDPxE1? M3v4UFI{QDR2MEO4
TE381.T NEXPSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ZT2ZzOTBizszN M1jjWlczKGh? NGjX[VlFVVOR NIm4fItKSzVyPUGwJO69VQ>? NYLWbYIyOjN6NESwN|g>
TK-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfMSWtSOTBizszN NVLBTFFSPzJiaB?= MVPEUXNQ NHKwUXFKSzVyPUGwJO69VQ>? Mm[4NlM5PDRyM{i=
U2OS M1PoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr0UFAyOCEQvF2= NG\XdYk4OiCq NHTYVFFFVVOR MV\JR|UxRTFyIN88US=> MVWyN|g1PDB|OB?=
U251 M13D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiwTmYyOCEQvF2= MX[3NkBp M4T1V2ROW09? NEPT[WFKSzVyPUGwJO69VQ>? NVnoVHF1OjN6NESwN|g>
UACC-812 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTyNVAh|ryP NXXDbI5xPzJiaB?= MkP4SG1UVw>? NFG5WmxKSzVyPUGwJO69VQ>? NFH6XmwzOzh2NECzPC=>
YAPC M1ywXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTv[YYyOCEQvF2= NFvo[oI4OiCq NX;P[YhuTE2VTx?= Ml7pTWM2OD1zMDFOwG0> NXu0XnE2OjN6NESwN|g>
ZR-75-1 NVzDR3B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm0dogyOCEQvF2= MYi3NkBp MVvEUXNQ NHXkUHlKSzVyPUGwJO69VQ>? NV\oWGpUOjN6NESwN|g>
A375 MXPGeY5kfGmxbjDhd5NigQ>? NWnSU2h5OS5{IN88US=> MkH2OEBp NFriXnRFVVOR M2fhRWlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S MV:yNlM5QTR5MR?=
YUSIT1 M2XQWGZ2dmO2aX;uJIF{e2G7 MoDvSG1UVw>? MmD6doVlfWOnZDDz[Y5{cXSrdnn0fUB4cXSqIFnDOVAhRiByLkWg{txO NIT5ZpozOjN6OUS3NS=>
MeWo MorzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVv3WpVQTE2VTx?= NUPiRZpRUUN3MDC9JFk5PyCwTR?= NInyR3MzPjBzOEWyOC=>
WiDr NHj5e|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEm1TY9FVVOR NUjWOmxuUUN3MDC9JFc3KG6P NUTYUFh5OjZyMUi1NlQ>
Colo-205 MmDQSpVv[3Srb36gZZN{[Xl? MmWzNUDPxE1? NH\ESlI1KGR? MXjEUXNQ MmTuTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm MWSyOVM5OTF3Mh?=
RBW-1 MVPGeY5kfGmxbjDhd5NigQ>? M1niUlEh|ryP MV\EUXNQ MVrOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NFr3VIMzPDh6NU[5NC=>
RBO-1 NF:4eY9HfW6ldHnvckBie3OjeR?= M{H6Z|Eh|ryP NFL0cFRFVVOR NHK0dJRKdmirYnn0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v Ml7BNlQ5QDV4OUC=
RBO-2 MoPnSpVv[3Srb36gZZN{[Xl? NIrLOGoyKM7:TR?= NF7XWZVFVVOR NV;2ZZZoUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? MWeyOFg5PTZ7MB?=
RBOW MWfGeY5kfGmxbjDhd5NigQ>? MoT1NUDPxE1? MWfEUXNQ MnG4TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NWH2U4lMOjR6OEW2PVA>
M257 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTWVHMyODBibl2= M2DVeVczKGh? NIS3Z2dFd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= MnnrNlM{OTd2NE[=
LCP MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL3[VYyODBibl2= NWnuc5MzPzJiaB?= MlW0TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=> NXmxOppyOjN|MUe0OFY>
WM266 NHjIXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr5NINSOTByIH7N NH7MS2M4OiCq M{TlU2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>? NXntdmJpOjN|MUe0OFY>
M257 NVHiTI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fLRVExOCCwTR?= MX23NkBp NILa[YdFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= M4XIWVI{OzF5NES2
LCP MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTkT3VjOTByIH7N NWnVfJJGPzJiaB?= MkLrTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? MWqyN|MyPzR2Nh?=
WM266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXIXY94OTByIH7N NIPuTpU4OiCq MVPJcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNGQhdXW2YX70ZZRqd25? MknDNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

体内研究 Dabrafenib(口服)抑制B-RafV600E突变的黑色素瘤(A375P)的生长,在免疫受损小鼠中皮下注射结肠癌(Colo205),Dabrafenib(口服)同样能抑制肿瘤生长。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 519.56
化学式

C23H20F3N5O2S2

CAS号 1195765-45-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品

Tags: 购买Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)供应商 | 采购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)价格 | Dabrafenib (GSK2118436)生产 | 订购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID